Evidence map›Paper›PMID 26367030›Full record

ArticlePloS one2015

Antibodies to S. aureus LukS-PV Attenuated Subunit Vaccine Neutralize a Broad Spectrum of Canonical and Non-Canonical Bicomponent Leukotoxin Pairs.

Rajan P Adhikari, Thomas Kort, Sergey Shulenin, Tulasikumari Kanipakala, Nader Ganjbaksh, Mary-Claire Roghmann, Frederick W Holtsberg, M Javad Aman

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Review
  3. Surface display of LukF-PV onFuture microbiology · 2025
    Article
  4. The Complex Intracellular Lifecycle ofInternational journal of molecular sciences · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. TBAScientific reports · 2019
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Rajan P AdhikariIntegrated Biotherapeutics Inc., Gaithersburg, Maryland, United States of America.
Thomas KortIntegrated Biotherapeutics Inc., Gaithersburg, Maryland, United States of America.
Sergey ShuleninIntegrated Biotherapeutics Inc., Gaithersburg, Maryland, United States of America.
Tulasikumari KanipakalaIntegrated Biotherapeutics Inc., Gaithersburg, Maryland, United States of America.
Nader GanjbakshIntegrated Biotherapeutics Inc., Gaithersburg, Maryland, United States of America.
Mary-Claire RoghmannDepartment of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, United States of America; VA Maryland Health Care System, Baltimore, Maryland, United States of America.
Frederick W HoltsbergIntegrated Biotherapeutics Inc., Gaithersburg, Maryland, United States of America.
M Javad AmanIntegrated Biotherapeutics Inc., Gaithersburg, Maryland, United States of America.
Integrated BioTherapeutics (United States) · USVA Maryland Health Care System · US

Funding

Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus diseaseR01AI111205 · NIAID · INTEGRATED BIOTHERAPEUTICS, INC. · PI M Javad Aman · 2015 to 2026
$6.9M
Multivalent Toxoid Vaccine for Prevention of S. aureus Invasive DiseasesR56AI111205 · NIAID · INTEGRATED BIOTHERAPEUTICS, INC. · PI AMAN, M JAVAD · 2014 to 2014
$647k
In vivo conjugated multivalent toxoid-polysaccharide vaccine for S. aureusR43AI106162 · NIAID · INTEGRATED BIOTHERAPEUTICS, INC. · PI ADHIKARI, RAJAN P · 2014 to 2015
$600k
A novel Structure Based Vaccine for staphylococcal alpha hemolysinR43AI098232 · NIAID · INTEGRATED BIOTHERAPEUTICS, INC. · PI ADHIKARI, RAJAN P · 2012 to 2013
$591k
NIAID NIH HHS AI098232NIAID NIH HHS AI106162NIAID NIH HHS AI111205NIAID NIH HHS R01 AI111205NIAID NIH HHS R43 AI098232NIAID NIH HHS R43 AI106162
6 · The paper itself

Abstract

S. aureus vaccine development has proven particularly difficult. The conventional approach to achieve sterile immunity through opsonophagocytic killing has been largely unsuccessful. S. aureus is highly toxigenic and a great body of evidence suggests that a successful future vaccine for this organism should target extracellular toxins which are responsible for host tissue destruction and immunosuppression. Major staphylococcal toxins are alpha toxin (a single subunit hemolysin) along with a group of bicomponent pore-forming toxins (BCPFT), namely Panton-Valentine leukocidin (PVL), gamma hemolysins (HlgCB and AB), LukAB and LukED. In our previous report, an attenuated mutant of LukS-PV (PVL- S subunit) named as "LukS-mut9" elicited high immunogenic response as well as provided a significant protection in a mouse sepsis model. Recent discovery of PVL receptors shows that mice lack receptors for this toxin, thus the reported protection of mice with the PVL vaccine may relate to cross protective responses against other homologous toxins. This manuscript addresses this issue by demonstrating that polyclonal antibody generated by LukS-mut9 can neutralize other canonical and non-canonical leukotoxin pairs. In this report, we also demonstrated that several potent toxins can be created by non-canonical pairing of subunits. Out of 5 pairs of canonical and 8 pairs of non-canonical toxins tested, anti-LukS-mut9 polyclonal antibodies neutralized all except for LukAB. We also studied the potential hemolytic activities of canonical and noncanonical pairs among biocomponent toxins and discovered that a novel non-canonical pair consisting of HlgA and LukD is a highly toxic combination. This pair can lyse RBC from different species including human blood far better than alpha hemolysin. Moreover, to follow-up our last report, we explored the correlation between the levels of pre-existing antibodies to new sets of leukotoxins subunits and clinical outcomes in adult patients with S. aureus bacteremia. We found that there is an inversed correlation between the antibody titer to sepsis for leukotoxins LukS-mut9, LukF-PV, HlgC, LukE and LukAB, suggesting the risk of sepsis was significantly lower in the patients with higher antibody titer against those toxins.

Indexed as

AdultAnimalsAntibodiesBacterial ProteinsBacterial ToxinsCross ReactionsCytotoxicity Tests, ImmunologicExotoxinsFemaleHumansLeukocidinsMice, Inbred BALB CMice, Inbred ICRNeutralization TestsRabbitsStaphylococcal InfectionsAntibodiesBacterial ProteinsBacterial ToxinsExotoxinsleukocidin AB, Staphylococcus aureusLeukocidinsleukocidin S-component protein, StaphylococcusLukD protein, Staphylococcus aureusPanton-Valentine leukocidinStaphylococcal VaccinesVaccines, Attenuated

Identifiers

PMID26367030
PMCPMC4569305
OpenAlexW2242450982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.